Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

This was probably the reason for the spike

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
maumar Member Profile
Member Level 
Followed By 4
Posts 356
Boards Moderated 0
Alias Born 09/28/12
160x600 placeholder
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 7/23/2019 4:01:00 PM
J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma Dow Jones News - 7/19/2019 7:45:00 AM
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALE... PR Newswire (US) - 7/19/2019 7:00:00 AM
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Te... PR Newswire (US) - 7/17/2019 8:00:00 AM
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire (US) - 7/12/2019 11:59:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/3/2019 4:02:19 PM
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Techno... PR Newswire (US) - 6/25/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 8:20:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 1:41:16 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/7/2019 5:11:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:45:58 PM
Halozyme To Participate In Upcoming Investor Conferences PR Newswire (US) - 6/4/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 5:24:28 PM
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire (US) - 5/22/2019 1:05:00 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:11:52 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:08:35 PM
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire (US) - 5/13/2019 8:01:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 4:14:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 4:07:11 PM
Halozyme Reports First Quarter 2019 Results PR Newswire (US) - 5/7/2019 4:01:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/6/2019 4:02:13 PM
Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development PR Newswire (US) - 5/6/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2019 5:08:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:30:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:26:35 PM
maumar Member Level  Monday, 02/25/19 03:47:30 PM
Re: None
Post # of 5652 
This was probably the reason for the spike in volume and price today.

"Phase III COLUMBA study comparing the subcutaneous formulation of daratumumab to the intravenous formulation in patients with relapsed or refractory multiple myeloma met both co-primary endpoints
Results show that daratumumab administered subcutaneously was non-inferior in efficacy and pharmacokinetics as compared to daratumumab administered intravenously
Data will be discussed with health authorities to prepare for regulatory filings in support of bringing convenience of subcutaneous daratumumab option to patients"

https://globenewswire.com/news-release/2019/02/25/1741776/0/en/Genmab-Announces-Positive-Topline-Results-in-Phase-III-COLUMBA-Study-of-Subcutaneous-Daratumumab.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist